Wall Street brokerages predict that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report earnings per share (EPS) of $0.56 for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings, with the lowest EPS estimate coming in at $0.43 and the highest estimate coming in at $0.68. Teva Pharmaceutical Industries posted earnings of $0.93 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 39.8%. The company is scheduled to report its next earnings report on Thursday, February 14th.
On average, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.91 per share for the current fiscal year, with EPS estimates ranging from $2.77 to $3.03. For the next financial year, analysts anticipate that the business will post earnings of $2.80 per share, with EPS estimates ranging from $2.20 to $3.30. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The firm had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.54 billion. During the same period in the prior year, the company earned $1.00 earnings per share. The company’s quarterly revenue was down 19.4% on a year-over-year basis.
NYSE TEVA traded down $0.39 on Friday, hitting $23.45. 6,637,061 shares of the company’s stock were exchanged, compared to its average volume of 10,918,274. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a 52 week low of $11.44 and a 52 week high of $25.96. The stock has a market capitalization of $24.13 billion, a PE ratio of 7.39, a PEG ratio of 7.28 and a beta of 0.77.
In related news, VP Richard Daniell sold 2,488 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the sale, the vice president now directly owns 2,488 shares in the company, valued at $58,940.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares of the company’s stock, valued at $56,334.96. The disclosure for this sale can be found here. Insiders have sold 6,531 shares of company stock valued at $152,749 over the last quarter. Company insiders own 0.43% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. Dimensional Fund Advisors LP increased its holdings in Teva Pharmaceutical Industries by 16.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,185,541 shares of the company’s stock valued at $20,261,000 after purchasing an additional 168,658 shares during the period. Legal & General Group Plc increased its holdings in Teva Pharmaceutical Industries by 14.6% in the first quarter. Legal & General Group Plc now owns 611,919 shares of the company’s stock valued at $10,458,000 after purchasing an additional 77,766 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at $293,000. DnB Asset Management AS increased its holdings in Teva Pharmaceutical Industries by 13.6% in the second quarter. DnB Asset Management AS now owns 77,700 shares of the company’s stock valued at $1,890,000 after purchasing an additional 9,300 shares during the period. Finally, IFM Investors Pty Ltd increased its holdings in Teva Pharmaceutical Industries by 52.8% in the second quarter. IFM Investors Pty Ltd now owns 43,300 shares of the company’s stock valued at $1,053,000 after purchasing an additional 14,960 shares during the period. Institutional investors and hedge funds own 65.10% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.